 Home > Active Ingredient News > Antitumor Therapy > Eur Urol: Evaluation of the efficacy and safety of stereotactic radiotherapy and short-term pembrolizumab in the treatment of oligometastatic renal cell carcinoma

Eur Urol: Evaluation of the efficacy and safety of stereotactic radiotherapy and short-term pembrolizumab in the treatment of oligometastatic renal cell carcinoma

 Last Update: 2022-01-08
 Source: Internet
 Author: User

Tags

xyzal 5 mg

checkers 2 5

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Metastasis-oriented therapy is a long-term treatment option for selected patients with oligometastatic renal cell carcinoma (RCC)
.
Because RCC has long been believed to be bio-resistant, radiotherapy has not been widely used

Stereotactic ablation radiotherapy (SABR) is an option for the treatment of oligometastatic clear cell renal cell carcinoma (ccRCC), but it is limited due to the lack of prospective clinical trial data.
Stereotactic ablation radiotherapy (SABR) is the treatment of oligometastasis An option for clear cell renal cell carcinoma (ccRCC), but limited due to lack of prospective clinical trial data

Recently, researchers from Australia published an article in the journal Eur Urol.
In the RAPPORT trial , they evaluated the safety of short-term anti-programmed death receptor-1 immunotherapy in patients with oligometastatic ccRCC after metastatic irradiation.
Sexuality and effectiveness
.

In the RAPPORT trial, the safety and effectiveness of short-term anti-programmed death receptor-1 immunotherapy after metastatic irradiation in patients with oligometastatic ccRCC was evaluated.
In the RAPPORT trial, patients with oligometastatic ccRCC were evaluated for after irradiation the transfer, re-programmed -1 short-term anti-death receptor immune safety of the treatment and the effectiveness of the situation immunity

RAPPORT is a single-arm, multi-institution phase I/II trial (NCT02855203)
.
The patient has previously received two or less systemic treatments and has 1-5 ccRCC oligometastases

A total of 30 patients were included in the study, with a median age of 62 years
.
The median follow-up time was 28 months

Duration of response (A) and cumulative incidence of treatment failure (B)

In summary, SABR and short-term pembrolizumab are well tolerated in the treatment of oligometastatic ccRCC and have good local control
.
The response is long-lasting and the PFS result is good, so it is worthy of further research

SABR and short-term pembrolizumab in the treatment of oligometastatic ccRCC are well tolerated and have good local control

Original source:

Shankar Siva, Mathias Bressel, Simon T Wood et al.

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial .

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.